The largest experience with vinflunine use in platinum-pretreated patients with metastatic urothelial cancer
Metastatic urothelial cancer (mUC) is a difficult-to-treat indication that requires treatment optimization particularly after cisplatin-based chemotherapy failure. Vinflunine is the only available agent for platinum-pretreated patients with mUC in Europe.
In the pivotal randomized phase III clinical study, vinflunine proved significant improvement of OS (6.9 vs. 4.3 months) in comparison to best supportive care and also a good tolerability profile consistent with expected class effects with the main toxicities being neutropenia and constipation. More than 28,000 patients were treated with vinflunine since 2008.
In the Genitourinary Cancer Symposium in San Francisco in february 2018, results of seven multicenter real-world studies with vinflunine (REVEAL) were presented. Compared to clinical trial data, real-world data have the advantage of representing a broader population, often over longer period of time, and provides information on comparators and outcomes that are not a part of the controlled clinical studies.
Source: Passalacqua R, Medioni J, Castellano D et al. Real world evidence of vinflunine in metastatic urothelial cancer: a systematic review of seven European studies. Presented at 2018 Genitourinary Cancer Symposium, San Francisco, February 2018.